Workflow
Viking Therapeutics(VKTX)
icon
Search documents
Is Viking Therapeutics the Next Big Biotech Bet?
The Motley Fool· 2025-08-01 23:00
Core Viewpoint - The article discusses the investment recommendation for Viking Therapeutics by The Motley Fool, highlighting its potential as a promising stock in the market [1] Company Summary - Viking Therapeutics is recommended by The Motley Fool, indicating a positive outlook for the company's stock performance [1]
Viking Therapeutics Q2: Confidently Continuing The Recovery
Seeking Alpha· 2025-07-25 14:15
Core Insights - JR Research is recognized as a top analyst in technology, software, and internet sectors, focusing on growth and GARP strategies [1] - The investment approach emphasizes identifying attractive risk/reward opportunities with robust price action to generate alpha above the S&P 500 [1][2] - The investment group Ultimate Growth Investing specializes in high-potential opportunities across various sectors with a focus on strong growth potential and contrarian plays [3] Investment Strategy - The strategy combines sharp price action analysis with fundamental investing, avoiding overhyped stocks while targeting battered stocks with recovery potential [2] - The investment outlook is typically 18 to 24 months for the thesis to materialize, aiming for robust fundamentals and attractive valuations [3] Target Audience - The group is designed for investors looking to capitalize on growth stocks with strong fundamentals, buying momentum, and turnaround plays [3]
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
ZACKS· 2025-07-24 15:46
Core Insights - Viking Therapeutics (VKTX) reported a second-quarter 2025 loss of $0.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $0.44, and compared to a loss of $0.20 per share in the same quarter last year [1][7] - The company currently has no approved products and has not generated any revenues [1] Financial Performance - Research and development (R&D) expenses for the quarter were $60.2 million, a significant increase from $23.8 million in the prior year, driven by higher costs related to clinical studies and manufacturing, as well as increased employee-related expenses [2] - General and administrative expenses rose to $14.4 million, reflecting a 40% year-over-year increase, primarily due to higher employee-related costs [2] - As of June 30, 2025, Viking had cash, cash equivalents, and short-term investments totaling $808 million, down from $852 million as of March 31, 2025 [4] Market Reaction - Shares of VKTX fell 8% in after-market trading following the announcement of a wider-than-expected loss due to increased operating expenses [3] Future Guidance - Viking indicated that R&D expenses are expected to rise sequentially by approximately 25% to one-third in the third and fourth quarters of 2025 compared to the second quarter [5] Pipeline Developments - Viking is developing VK2735, a dual GLP-1 and GIP receptor agonist, for obesity treatment, with ongoing clinical studies for both oral and subcutaneous formulations [8] - The company launched the phase III VANQUISH program to evaluate VK2735 SC in adult patients, targeting enrollment of about 4,500 participants for VANQUISH-1 and around 1,100 for VANQUISH-2 [9] - An oral formulation of VK2735 is being evaluated in the phase II VENTURE-Oral Dosing study, with data expected by the end of the year [10] - Viking plans to file an investigational new drug application with the FDA in Q4 2025 for an internally developed amylin agonist program aimed at treating obesity [10]
Viking Therapeutics(VKTX) - 2025 Q2 - Earnings Call Transcript
2025-07-23 21:32
Financial Data and Key Metrics Changes - Research and development expenses increased to $60.2 million for Q2 2025 from $23.8 million in Q2 2024, primarily due to clinical study costs and manufacturing expenses [8][9] - General and administrative expenses rose to $14.4 million for Q2 2025 from $10.3 million in Q2 2024, mainly due to stock-based compensation and salaries [9] - The net loss for Q2 2025 was $65.6 million, or $0.58 per share, compared to a net loss of $22.3 million, or $0.20 per share, in Q2 2024 [9] - For the first six months of 2025, research and development expenses totaled $101.5 million, up from $47.9 million in the same period in 2024 [10] - The net loss for the first half of 2025 was $111.2 million, or $0.99 per share, compared to a net loss of $49.6 million, or $0.46 per share, in the first half of 2024 [10][11] - Cash, cash equivalents, and short-term investments decreased to $8 million as of June 30, 2025, from $9 million at the end of 2024 [11] Business Line Data and Key Metrics Changes - The VK2735 program for obesity is advancing with both oral and subcutaneous formulations, with the initiation of the Vanquish Phase III registration program [5][6] - The Phase II trial for the oral tablet formulation of VK2735 completed enrollment, with results expected later in the year [6][21] - The company is also progressing with a new program evaluating novel agonists of the amylin receptor, with an IND filing expected in Q4 2025 [22] Market Data and Key Metrics Changes - The Vanquish Phase III studies will evaluate VK2735 in adults with obesity and those with type 2 diabetes, targeting a total enrollment of approximately 4,500 and 1,100 participants, respectively [15][16] - The primary endpoint of the trials is the percent change in body weight from baseline after 78 weeks of treatment [16] Company Strategy and Development Direction - The company aims to provide both oral and subcutaneous formulations of VK2735 to cater to different patient preferences and mitigate safety challenges [17][18] - Viking Therapeutics is maintaining fiscal discipline and a strong balance sheet to support the advancement of VK2735 through Phase III trials and other key programs [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing studies and the strong demand for new weight loss therapeutics, indicating a positive outlook for the VK2735 program [23] - The company is focused on executing its core clinical strategy and is excited about the progress made in its development programs [5][6] Other Important Information - The company has achieved a comprehensive manufacturing agreement to support the potential commercialization of VK2735 [7] - Viking Therapeutics is preparing for the transition to auto injectors for VK2735 in early 2026, with plans for a bioequivalence study [110] Q&A Session Summary Question: Will the Phase II readout include data from all cohorts? - Yes, it will include all cohorts as it is a parallel cohort study [28] Question: Do you have an oral dose in mind for the monthly dosing study? - No specific dose has been determined yet as Phase II oral data is still pending [34] Question: Can you discuss the rationale for the top dose in the Phase III trial? - The decision to increase the top dose was based on encouraging tolerability and efficacy observed in previous studies [39] Question: What are the expectations for the oral Phase II data? - The company is looking for mid to high single-digit weight loss percentages, ideally around 8% [74] Question: How will placebo patients be motivated to stay in the study? - Regular visits and eligibility for open-label extensions are expected to help maintain participation [104] Question: What does the amylin agonist program need to show in Phase I? - The program should demonstrate impact on body weight and a favorable tolerability profile [124]
Viking Therapeutics(VKTX) - 2025 Q2 - Earnings Call Transcript
2025-07-23 21:30
Financial Data and Key Metrics Changes - Research and development expenses for Q2 2025 were $60.2 million, up from $23.8 million in Q2 2024, primarily due to increased clinical study costs and manufacturing expenses [7] - General and administrative expenses for Q2 2025 were $14.4 million, compared to $10.3 million in Q2 2024, driven by higher stock-based compensation and salaries [8] - The net loss for Q2 2025 was $65.6 million, or $0.58 per share, compared to a net loss of $22.3 million, or $0.20 per share in Q2 2024 [8] - For the first six months of 2025, research and development expenses totaled $101.5 million, up from $47.9 million in the same period in 2024 [9] - The net loss for the first half of 2025 was $111.2 million, or $0.99 per share, compared to a net loss of $49.6 million, or $0.46 per share in the first half of 2024 [9] - Cash, cash equivalents, and short-term investments as of June 30, 2025, were $800 million, down from $930 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - The VK2735 program for obesity has advanced to Phase III with the initiation of the Vanquish registration program, which includes two trials targeting adults with obesity and those with type 2 diabetes [4][14] - The oral formulation of VK2735 has shown promising results in Phase I studies, achieving up to 8.2% weight loss after 28 days of daily dosing [18] - The VENTURE Phase II study for VK2735 demonstrated statistically significant weight loss effects, with reductions in mean body weight of up to 14.7% [12] Market Data and Key Metrics Changes - The company is focusing on the obesity market, which is seeing strong demand for new and differentiated weight loss therapeutics, as evidenced by rapid enrollment in VK2735 trials [22][23] - The competitive landscape includes other agents, but the company believes there is room for multiple products in the obesity treatment market [112] Company Strategy and Development Direction - The company is committed to advancing its clinical pipeline, particularly the VK2735 obesity program, while maintaining fiscal discipline and a strong balance sheet to support ongoing and future trials [21][22] - The strategy includes both subcutaneous and oral formulations of VK2735 to provide treatment options for patients [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical trials and the potential for VK2735 to meet significant unmet needs in obesity treatment [22] - The company plans to file an IND for its amylin receptor agonist program in Q4 2025, indicating a commitment to expanding its pipeline [21] Other Important Information - The company has established a comprehensive manufacturing agreement to support the potential commercialization of VK2735 [6] - Management highlighted the importance of maintaining participant engagement in placebo groups during long-term studies [100] Q&A Session Summary Question: Will the Phase II readout include data from all cohorts? - Yes, it will include all cohorts as it is a parallel cohort study [28] Question: What is the rationale for the dosing in the Phase III trial? - The decision to increase the top dose to 17.5 mg was based on encouraging tolerability and efficacy observed in previous studies [37] Question: How will the company motivate placebo patients to remain in the study? - The eligibility for an open-label extension after the trial is expected to help maintain participation [100] Question: What are the expectations for the oral program's Phase II data? - The company is looking for significant weight loss and a favorable tolerability profile to consider advancing to Phase III [119]
Viking Therapeutics(VKTX) - 2025 Q2 - Quarterly Report
2025-07-23 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...
Viking Therapeutics(VKTX) - 2025 Q2 - Quarterly Results
2025-07-23 20:05
[Executive Summary & Recent Developments](index=1&type=section&id=Executive%20Summary%20%26%20Recent%20Developments) Viking Therapeutics, a clinical-stage biopharmaceutical company, achieved significant clinical milestones in H1 2025 and maintains a strong financial position to advance its pipeline [Company Overview](index=1&type=section&id=Company%20Overview) Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The CEO highlighted significant clinical milestones achieved in the first half of 2025 and a strong balance sheet to support ongoing development - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders[2](index=2&type=chunk) - CEO Brian Lian highlighted significant execution and clinical milestones in H1 2025, including the initiation of the VK2735 Phase 3 VANQUISH program and completion of enrollment for the Phase 2 VENTURE-Oral Dosing study[3](index=3&type=chunk) - The company completed Q2 with a strong balance sheet, holding **$808 million** in cash, providing runway for advancing VK2735 through Phase 3 and supporting other key development programs[3](index=3&type=chunk)[5](index=5&type=chunk)[21](index=21&type=chunk) [Highlights from the Quarter Ended June 30, 2025, and Other Recent Events](index=1&type=section&id=Highlights%20from%20the%20Quarter%20Ended%20June%2030%2C%202025%2C%20and%20Other%20Recent%20Events) Key achievements during the quarter include the initiation of Phase 3 trials for subcutaneous VK2735, completion of enrollment for the Phase 2 oral VK2735 study with results expected in 2H25, and continued progress on the amylin program with an IND planned for Q4 2025. The company also reported a strong quarter-end cash position - Phase 3 VANQUISH Registration Trials for VK2735 in Obesity are underway[5](index=5&type=chunk) - Enrollment for the Phase 2 VENTURE-Oral Dosing Trial is completed, with top-line results expected in **2H25**[5](index=5&type=chunk) - Continued progress with the Amylin Program, with an IND planned for **4Q25**[5](index=5&type=chunk) - Strong Quarter-End Cash Position of **$808 million**[5](index=5&type=chunk)[21](index=21&type=chunk) [Pipeline and Recent Corporate Highlights](index=1&type=section&id=Pipeline%20and%20Recent%20Corporate%20Highlights) Viking Therapeutics is advancing its obesity pipeline with Phase 3 trials for subcutaneous VK2735, completed enrollment for oral VK2735 Phase 2, and an IND planned for its DACRA program [Phase 3 VANQUISH Registration Trials for Subcutaneous VK2735 Underway](index=2&type=section&id=Phase%203%20VANQUISH%20Registration%20Trials%20Underway%20for%20VK2735%20in%20Obesity) Viking initiated the Phase 3 VANQUISH clinical program for subcutaneous VK2735, a dual GLP-1/GIP agonist, for obesity. This program includes two randomized, double-blind, placebo-controlled studies (VANQUISH-1 and VANQUISH-2) evaluating efficacy and safety over 78 weeks, building on positive Phase 2 VENTURE results - VK2735 is a wholly owned long-acting dual agonist of GLP-1 and GIP receptors for obesity and metabolic disorders[6](index=6&type=chunk) - Phase 2 VENTURE study showed statistically significant body weight reductions up to **14.7%** after **13 weekly doses**, with encouraging safety and tolerability[6](index=6&type=chunk) - The VANQUISH Phase 3 program includes two studies: VANQUISH-1 (approx. **4,500 adults** with obesity/overweight with co-morbidity) and VANQUISH-2 (approx. **1,100 adults** with type 2 diabetes and obesity/overweight)[7](index=7&type=chunk) - Primary endpoint for Phase 3 trials is percent change in body weight from baseline after **78 weeks**[8](index=8&type=chunk) [Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25](index=2&type=section&id=Phase%202%20VENTURE-Oral%20Dosing%20Trial%20Enrollment%20Completed%3B%20Top-Line%20Results%20Expected%202H25) Enrollment for the Phase 2 VENTURE-Oral Dosing trial of VK2735 in subjects with obesity has been completed, with approximately 280 patients enrolled. Top-line results are anticipated in the second half of 2025. This oral formulation aims to provide a convenient treatment option and potential transition from subcutaneous therapy - Oral tablet formulation of VK2735 is being developed as an attractive treatment option, potentially allowing transition from subcutaneous formulation[9](index=9&type=chunk)[10](index=10&type=chunk) - Phase 1 oral VK2735 trial demonstrated dose-dependent weight reductions up to **8.2%** after **28 days** and up to **8.3%** at Day **57** follow-up, with encouraging safety and tolerability[11](index=11&type=chunk) - Phase 2 VENTURE-Oral Dosing trial, initiated in January 2025, is a randomized, double-blind, placebo-controlled study evaluating safety, tolerability, PK, and weight loss efficacy of once-daily oral VK2735 for **13 weeks**[12](index=12&type=chunk) - Enrollment for the Phase 2 VENTURE-Oral trial was completed in March 2025, with approximately **280 patients**, and results are expected in **2H25**[13](index=13&type=chunk) [Continued Progress with Dual Amylin and Calcitonin Receptor Agonist (DACRA) Program; IND Expected 4Q25](index=3&type=section&id=Continued%20Progress%20with%20Dual%20Amylin%20and%20Calcitonin%20Receptor%20Agonist%20%28DACRA%29%20Program%3B%20IND%20Expected%204Q25) Viking is advancing its internally developed Dual Amylin and Calcitonin Receptor Agonist (DACRA) program for obesity, with an Investigational New Drug (IND) application planned for submission in the fourth quarter of 2025, supported by positive preclinical data showing reduced food intake and improved metabolic profiles in rodents - Viking announced a new, internally developed DACRA program for obesity in **2024**, targeting amylin and calcitonin receptors[13](index=13&type=chunk) - In vivo data presented at ADA **2024** showed Viking's DACRAs reduced food intake and improved metabolic profile in rodents[13](index=13&type=chunk) - Viking plans to file an IND application for the DACRA program in **Q4 2025**[14](index=14&type=chunk) [Upcoming Investor Events](index=3&type=section&id=Upcoming%20Investor%20Events) Viking management will participate in several investor conferences during July and September 2025, including BTIG Virtual Biotechnology, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Bernstein's Healthcare Forum, and Stifel Virtual Cardiometabolic Forum - Viking management will participate in the following upcoming investor events: * BTIG Virtual Biotechnology Conference **2025** (July **29 – 30, 2025**) * Cantor Global Healthcare Conference (September **3 – 5, 2025**) * Morgan Stanley **23rd** Annual Global Healthcare Conference (September **8 - 10, 2025**) * Bernstein's **2nd** Annual Healthcare Forum (September **23 - 25, 2025**) * Stifel **2025** Virtual Cardiometabolic Forum (September **30, 2025**)[14](index=14&type=chunk)[15](index=15&type=chunk) [Financial Results](index=4&type=section&id=Financial%20Results) Viking Therapeutics reported increased net losses for Q2 and H1 2025, primarily driven by higher research and development and general and administrative expenses, while maintaining a strong cash position [Second Quarter ended June 30, 2025 and 2024](index=4&type=section&id=Second%20Quarter%20ended%20June%2030%2C%202025%20and%202024) For Q2 2025, Viking reported a net loss of $65.6 million ($0.58 per share), significantly higher than the $22.3 million net loss ($0.20 per share) in Q2 2024, primarily due to increased R&D and G&A expenses Second Quarter Financial Performance (Q2 2025 vs Q2 2024) | Metric | Q2 2025 (in thousands) | Q2 2024 (in thousands) | Change (YoY) | | :-------------------------- | :--------------------- | :--------------------- | :----------- | | Research and development | $60,153 | $23,769 | +153.1% | | General and administrative | $14,421 | $10,285 | +40.2% | | Net loss | $(65,561) | $(22,250) | +194.6% | | Basic and diluted net loss per share | $(0.58) | $(0.20) | +190.0% | - Increase in R&D expenses primarily due to increased clinical studies, manufacturing, pre-clinical studies, stock-based compensation, and salaries and benefits[15](index=15&type=chunk) - Increase in G&A expenses primarily due to increased stock-based compensation and salaries and benefits, partially offset by decreased legal and patent services[16](index=16&type=chunk) [Six Months Ended June 30, 2025 and 2024](index=4&type=section&id=Six%20Months%20Ended%20June%2030%2C%202025%20and%202024) For the first six months of 2025, Viking reported a net loss of $111.2 million ($0.99 per share), an increase from $49.6 million ($0.46 per share) in the same period of 2024, driven by higher R&D and G&A expenses, partially offset by increased interest income Six Months Financial Performance (H1 2025 vs H1 2024) | Metric | H1 2025 (in thousands) | H1 2024 (in thousands) | Change (YoY) | | :-------------------------- | :--------------------- | :--------------------- | :----------- | | Research and development | $101,543 | $47,872 | +112.1% | | General and administrative | $28,500 | $20,255 | +40.7% | | Net loss | $(111,190) | $(49,606) | +124.1% | | Basic and diluted net loss per share | $(0.99) | $(0.46) | +115.2% | - Increase in R&D expenses primarily due to increased clinical studies, manufacturing, stock-based compensation, and salaries and benefits, partially offset by decreased pre-clinical studies[18](index=18&type=chunk) - Increase in G&A expenses primarily due to increased stock-based compensation, legal and patent services, and insurance, partially offset by decreased third-party consultants[19](index=19&type=chunk) [Balance Sheet as of June 30, 2025](index=5&type=section&id=Balance%20Sheet%20as%20of%20June%2030%2C%202025) As of June 30, 2025, Viking held $808 million in cash, cash equivalents, and short-term investments, a decrease from $903 million at December 31, 2024. Total assets decreased to $827.9 million, while total liabilities increased to $32.4 million Balance Sheet Highlights (June 30, 2025 vs December 31, 2024) | Metric | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | Change | | :------------------------------------ | :----------------------------- | :----------------------------- | :----- | | Cash, cash equivalents and short-term investments | $807,724 | $902,612 | $(94,888) | | Total current assets | $827,017 | $907,216 | $(80,199) | | Total assets | $827,851 | $908,321 | $(80,470) | | Total current liabilities | $31,980 | $27,413 | +$4,567 | | Total liabilities | $32,390 | $28,043 | +$4,347 | | Total stockholders' equity | $795,461 | $880,278 | $(84,817) | [Additional Information](index=5&type=section&id=Additional%20Information) This section provides details on the upcoming Q2 2025 conference call, an overview of Viking Therapeutics' pipeline, forward-looking statement disclaimers, and condensed financial statements [Conference Call](index=5&type=section&id=Conference%20Call) Viking will host a conference call on July 23, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results, with replay and webcast options available - Conference call to discuss Q2 **2025** financial results scheduled for July **23, 2025**, at **4:30 p.m. ET**[1](index=1&type=chunk)[22](index=22&type=chunk) - Dial-in: **(844) 850-0543** (U.S.) or **(412) 317-5199** (International). Webcast available at **http://ir.vikingtherapeutics.com/webcasts**[22](index=22&type=chunk) [About Viking Therapeutics, Inc.](index=5&type=section&id=About%20Viking%20Therapeutics%2C%20Inc.) Viking Therapeutics is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Its pipeline includes VK2735 (dual GLP-1/GIP agonist for obesity, subcutaneous in Phase 3, oral in Phase 2), VK2809 (selective thyroid hormone receptor beta agonist for NASH/fibrosis and NAFLD/elevated LDL-C), DACRAs for obesity, and VK0214 (selective thyroid hormone receptor beta agonist for X-ALD) - Viking is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders[23](index=23&type=chunk) - Key pipeline assets include: * **VK2735:** Dual GLP-1/GIP agonist for obesity (subcutaneous in Phase 3, oral in Phase 2) * **VK2809:** Selective thyroid hormone receptor beta agonist for NASH/fibrosis (Phase 2b successful) and NAFLD/elevated LDL-C (Phase 2a successful) * **DACRAs:** Internally developed dual amylin and calcitonin receptor agonists for obesity * **VK0214:** Selective thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy (X-ALD) (Phase 1b promising)[23](index=23&type=chunk)[24](index=24&type=chunk) [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements subject to risks and uncertainties, including those related to clinical trial success, costs, timing, regulatory requirements, and the replication of prior results. Actual results may differ materially - Press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of **1995**[26](index=26&type=chunk) - Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with clinical trial success, cost, timing, regulatory requirements, and replication of prior results[26](index=26&type=chunk) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This table provides the unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025, and 2024, detailing revenues, operating expenses, other income/expense, net loss, and comprehensive loss Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands) | | | | Three Months Ended | | | | Six Months Ended | | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | | | | June 30, | | | | June 30, | | | | 2025 | | | 2024 | | 2025 | | 2024 | | Revenues | $ | — | $ | — | $ | — | $ | — | | Operating expenses: | | | | | | | | | | Research and development | | 60,153 | | 23,769 | | 101,543 | | 47,872 | | General and administrative | | 14,421 | | 10,285 | | 28,500 | | 20,255 | | Total operating expenses | | 74,574 | | 34,054 | | 130,043 | | 68,127 | | Loss from operations | | (74,574) | | (34,054) | | (130,043) | | (68,127) | | Other income (expense): | | | | | | | | | | Amortization of financing costs | | (24) | | (18) | | (48) | | (46) | | Interest income, net | | 9,033 | | 11,820 | | 18,897 | | 18,565 | | Realized gain on investments, net | | 4 | | 2 | | 4 | | 2 | | Total other income, net | | 9,013 | | 11,804 | | 18,853 | | 18,521 | | Net loss | | (65,561) | | (22,250) | | (111,190) | | (49,606) | | Other comprehensive loss, net of tax: | | | | | | | | | | Unrealized gain (loss) on securities | | 26 | | (699) | | 589 | | (1,824) | | Foreign currency translation gain (loss) | | 24 | | 26 | | 33 | | (59) | | Comprehensive loss | $ | (65,511) | $ | (22,923) | $ | (110,568) | $ | (51,489) | | Basic and diluted net loss per share | $ | (0.58) | $ | (0.20) | $ | (0.99) | $ | (0.46) | | Weighted-average shares used to compute basic | | | | | | | | | | and diluted net loss per share | | 112,134 | | 110,390 | | 112,102 | | 106,924 | [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table presents the unaudited condensed consolidated balance sheets as of June 30, 2025, and December 31, 2024, detailing assets, liabilities, and stockholders' equity Condensed Consolidated Balance Sheets (in thousands) | | June 30, | | | December 31, | | :--- | :--- | :--- | :--- | :--- | | | 2025 | | | 2024 | | | (Unaudited) | | | | | Assets | | | | | | Current assets: | | | | | | Cash and cash equivalents | $ | 33,880 | $ | 26,676 | | Short-term investments – available-for-sale | | 773,844 | | 875,936 | | Prepaid clinical trial and preclinical study costs | | 16,478 | | 3,476 | | Prepaid expenses and other current assets | | 2,815 | | 1,128 | | Total current assets | | 827,017 | | 907,216 | | Right-of-use assets | | 780 | | 1,003 | | Deferred financing costs | | 8 | | 56 | | Deposits | | 46 | | 46 | | Total assets | $ | 827,851 | $ | 908,321 | | Liabilities and stockholders' equity | | | | | | Current liabilities: | | | | | | Accounts payable | $ | 5,494 | $ | 9,813 | | Other accrued liabilities | | 26,018 | | 17,111 | | Lease liability, current | | 468 | | 489 | | Total current liabilities | | 31,980 | | 27,413 | | Lease liability, net of current portion | | 410 | | 630 | | Total long-term liabilities | | 410 | | 630 | | Total liabilities | | 32,390 | | 28,043 | | Commitments and contingencies | | | | | | Stockholders' equity: | | | | | | Preferred stock, $0.00001 par value: 10,000,000 shares authorized at June 30, 2025 | | | | | | and December 31, 2024; no shares issued and outstanding at June 30, 2025 and | | | | | | December 31, 2024 | | — | | — | | Common stock, $0.00001 par value: 300,000,000 shares authorized at June 30, 2025 | | | | | | and December 31, 2024; 112,329,709 shares issued and outstanding at June 30, 2025 | | | | | | and 111,573,519 shares issued and outstanding at December 31, 2024 | | 1 | | 1 | | Treasury stock at cost, no shares at June 30, 2025 and December 31, 2024 | | — | | — | | Additional paid-in capital | | 1,394,723 | | 1,368,972 | | Accumulated deficit | | (599,097) | | (487,907) | | Accumulated other comprehensive loss | | (166) | | (788) | | Total stockholders' equity | | 795,461 | | 880,278 | | Total liabilities and stockholders' equity | $ | 827,851 | $ | 908,321 | [Contacts](index=9&type=section&id=Contacts) Provides contact information for Viking Therapeutics' Chief Financial Officer, Greg Zante, and for investor and media relations through Vida Strategic Partners - Viking Therapeutics Contacts: * **Greg Zante**, Chief Financial Officer: **858-704-4672**, gzante@vikingtherapeutics.com * Vida Strategic Partners (Investors): **Stephanie Diaz**, **415-675-7401**, sdiaz@vidasp.com * Vida Strategic Partners (Media): **Tim Brons**, **415-675-7402**, tbrons@vidasp.com[31](index=31&type=chunk)
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Prnewswire· 2025-07-23 20:05
Core Insights - Viking Therapeutics reported significant clinical and financial developments in Q2 2025, including the initiation of the Phase 3 VANQUISH program for VK2735, aimed at treating obesity and type 2 diabetes [2][4] - The company ended the quarter with a strong cash position of $808 million, supporting ongoing clinical trials and development programs [5][16] Clinical Pipeline Updates - The VANQUISH Phase 3 program for VK2735 includes two studies targeting approximately 4,500 adults with obesity and 1,100 adults with type 2 diabetes, assessing the efficacy and safety of VK2735 administered weekly for 78 weeks [4][5] - The Phase 2 VENTURE-Oral Dosing study of VK2735's oral formulation completed enrollment with approximately 280 patients, with top-line results expected in the second half of 2025 [6][8] - VK2735 demonstrated statistically significant weight loss of up to 14.7% in previous trials, with a favorable safety profile [3][4] Financial Performance - Research and development expenses for Q2 2025 were $60.2 million, up from $23.8 million in Q2 2024, primarily due to increased clinical study costs [10][11] - General and administrative expenses rose to $14.4 million in Q2 2025 from $10.3 million in Q2 2024, driven by higher stock-based compensation [11] - The net loss for Q2 2025 was $65.6 million, compared to a net loss of $22.3 million in Q2 2024, reflecting increased operational costs [12] Balance Sheet Overview - As of June 30, 2025, Viking held cash, cash equivalents, and short-term investments totaling $808 million, a decrease from $903 million at the end of 2024 [16] - The total liabilities stood at $32.4 million, with stockholders' equity at $795.5 million [25]
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
ZACKS· 2025-07-21 14:41
Core Viewpoint - Investors are expected to focus on Viking Therapeutics' pipeline updates during the second-quarter 2025 results announcement on July 23, following a previous earnings miss of approximately 21% [1][6]. Company Overview - Viking Therapeutics currently has no marketed drugs, leading to an expected revenue of zero for the upcoming quarter. The Zacks Consensus Estimate predicts a loss of $0.44 per share [2][7]. Pipeline Developments - The company is advancing three key candidates: VK2735 for obesity, VK2809 for non-alcoholic steatohepatitis (NASH), and VK0214 for X-linked adrenoleukodystrophy (X-ALD) [2][5]. - The phase III VANQUISH program for VK2735 has commenced, focusing on a subcutaneous formulation for adult patients with or without type II diabetes (T2D) over 78 weeks. The program includes two studies: VANQUISH-1 targeting 4,500 participants and VANQUISH-2 targeting 1,100 participants [3][5]. - An oral formulation of VK2735 is being evaluated in a phase II VENTURE-Oral Dosing study, with data expected by the end of the year [4]. Clinical Development Updates - Investors are looking for updates on the dual amylin and calcitonin receptor agonist (DACRA) candidate, with plans to file an investigational new drug (IND) application for obesity by year-end [5]. - Updates on the NASH and X-ALD programs, including collaboration prospects, are also anticipated [5]. Earnings Performance - Viking's earnings history has been mixed, with two earnings beats and two misses over the last four quarters, resulting in a negative average surprise of 1.93%. The company's shares have decreased by 20% year-to-date, contrasting with a 2% decline in the industry [6][7].
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
The Motley Fool· 2025-07-20 08:48
Core Viewpoint - The biotechnology industry presents significant investment opportunities, particularly in pre-revenue companies with high price targets set by analysts, indicating potential for dramatic gains in a short time [1][4]. Group 1: Compass Pathways - Compass Pathways is developing a treatment for depression using synthetic psilocybin, with a current market cap of approximately $363 million, down from a peak of over $2 billion during the COVID-19 pandemic [5][10]. - Analysts have set a consensus price target of $15.78 for Compass Pathways, suggesting a potential gain of over 300% from current prices [5]. - The company reported positive results from the COMP005 trial for treatment-resistant depression (TRD), showing a 3.6-point improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) compared to the placebo group [8][9]. - The upcoming COMP006 study will further evaluate the efficacy of COMP360, with expectations that stronger results could significantly increase the stock's value [10]. Group 2: Viking Therapeutics - Viking Therapeutics, another clinical-stage drugmaker, has seen its market cap drop to approximately $3.6 billion from a peak of over $9 billion, with analysts projecting a price target of $90.26, indicating a potential increase of 181% [12]. - The company's lead candidate, VK2735, has shown promising results in weight loss, achieving a placebo-adjusted weight loss of 13% after 13 weeks of treatment [13]. - Viking Therapeutics is positioned to compete with established products like Zepbound, which generated $9.3 billion in annualized sales in the first quarter of this year [14]. - The company is currently conducting a phase 3 study to support a new drug application, which carries risks if tolerability issues arise [15].